Search Results

There are 102453 results for: content related to: Exenatide in acute ischemic stroke

  1. Glucagon-like peptide analogues for type 2 diabetes mellitus

    Intervention Review

    The Cochrane Library

    Deepson S. Shyangdan, Pamela Royle, Christine Clar, Pawana Sharma, Norman Waugh and Ailsa Snaith

    Published Online : 5 OCT 2011, DOI: 10.1002/14651858.CD006423.pub2

  2. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 6, June 2012, Pages: 546–554, M. S. Fineman, K. F. Mace, M. Diamant, T. Darsow, B. B. Cirincione, T. K. Booker Porter, L. A. Kinninger and M. E. Trautmann

    Version of Record online : 10 FEB 2012, DOI: 10.1111/j.1463-1326.2012.01561.x

  3. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 8, August 2011, Pages: 703–710, K. Y. Thong, B. Jose, N. Sukumar, M. L. Cull, A. P. Mills, T. Sathyapalan, W. Shafiq, A. S. Rigby, C. Walton, R. E. J. Ryder and on behalf of the ABCD nationwide exenatide audit contributors

    Version of Record online : 21 JUN 2011, DOI: 10.1111/j.1463-1326.2011.01393.x

  4. Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus

    The Journal of Clinical Pharmacology

    Volume 48, Issue 12, December 2008, Pages: 1389–1399, Dr Prajakti A. Kothare, Dr Helle Linnebjerg, Dr Yoshitaka Isaka, Mr Kazunori Uenaka, Dr Ayuko Yamamura, Dr Kwee Poo Yeo, Dr Amparo de la Peña, Dr Choo Hua Teng, Dr Kenneth Mace, Mr Mark Fineman, Dr Hirofumi Shigeta, Dr Yukikuni Sakata and Dr Shin Irie

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270008323750

  5. You have full text access to this OnlineOpen article
    Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Carol H. Wysham, Julio Rosenstock, Marion L. Vetter, Fang Dong, Peter Öhman and Nayyar Iqbal

    Version of Record online : 22 AUG 2017, DOI: 10.1111/dom.13056

  6. Application of model-based methods to characterize exenatide-loaded double-walled microspheres: In vivo release, pharmacokinetic/pharmacodynamic model, and in vitro and in vivo correlation

    Journal of Pharmaceutical Sciences

    Volume 101, Issue 10, October 2012, Pages: 3946–3961, Xingang Li, Liang Li, Xipei Wang, Yupeng Ren, Tianyan Zhou and Wei Lu

    Version of Record online : 29 JUN 2012, DOI: 10.1002/jps.23236

  7. Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic

    Internal Medicine Journal

    Volume 44, Issue 4, April 2014, Pages: 345–353, M. J. Carrington, Y.-K. Chan, S. Stewart, B. Sjouke, R. Brazilek and N. Cohen

    Version of Record online : 23 APR 2014, DOI: 10.1111/imj.12377

  8. You have free access to this content
    Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity

    British Journal of Pharmacology

    Volume 163, Issue 2, May 2011, Pages: 399–412, Nian Gong, Ai-Niu Ma, Li-Jie Zhang, Xiao-Su Luo, Yin-Hui Zhang, Michael Xu and Yong-Xiang Wang

    Version of Record online : 18 APR 2011, DOI: 10.1111/j.1476-5381.2011.01227.x

  9. You have full text access to this Open Access content
    Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks

    Journal of Diabetes Investigation

    Volume 2, Issue 3, June 2011, Pages: 210–217, Takashi Kadowaki, Mitsuyoshi Namba, Takeshi Imaoka, Ayuko Yamamura, Wakana Goto, Marilyn K. Boardman and Hideaki Sowa

    Version of Record online : 10 DEC 2010, DOI: 10.1111/j.2040-1124.2010.00084.x

  10. You have free access to this content
    Exenatide: a review from pharmacology to clinical practice

    Diabetes, Obesity and Metabolism

    Volume 11, Issue 6, June 2009, Pages: 544–556, R. Gentilella, C. Bianchi, A. Rossi and C. M. Rotella

    Version of Record online : 5 APR 2009, DOI: 10.1111/j.1463-1326.2008.01018.x

  11. No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 5, May 2013, Pages: 417–426, K. Tatarkiewicz, P. Belanger, G. Gu, D. Parkes and D. Roy

    Version of Record online : 7 DEC 2012, DOI: 10.1111/dom.12040

  12. Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials

    International Journal of Clinical Practice

    Robert S. Busch, James Ruggles, Jenny Han and Elise Hardy

    Version of Record online : 17 OCT 2017, DOI: 10.1111/ijcp.13029

  13. Once weekly exenatide: efficacy, tolerability and place in therapy

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 10, October 2013, Pages: 871–881, C. Wysham, M. Grimm and S. Chen

    Version of Record online : 24 MAR 2013, DOI: 10.1111/dom.12084

  14. You have full text access to this OnlineOpen article
    Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy

    International Journal of Clinical Practice

    Volume 66, Issue 12, December 2012, Pages: 1147–1157, G. S. Tobin, M. K. Cavaghan, B. J. Hoogwerf and J. B. McGill

    Version of Record online : 14 OCT 2012, DOI: 10.1111/ijcp.12032

  15. An overview of once-weekly glucagon-like peptide-1 receptor agonists—available efficacy and safety data and perspectives for the future

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 5, May 2011, Pages: 394–407, S. Madsbad, U. Kielgast, M. Asmar, C. F. Deacon, S. S. Torekov and J. J. Holst

    Version of Record online : 24 MAR 2011, DOI: 10.1111/j.1463-1326.2011.01357.x

  16. You have full text access to this OnlineOpen article
    Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 6, June 2013, Pages: 485–502, R. Balena, I. E. Hensley, S. Miller and A. H. Barnett

    Version of Record online : 12 NOV 2012, DOI: 10.1111/dom.12025

  17. You have full text access to this Open Access content
    Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes

    Journal of Diabetes Investigation

    Volume 2, Issue 6, December 2011, Pages: 448–456, Nobuya Inagaki, Kohjiro Ueki, Ayuko Yamamura, Hitoshi Saito and Takeshi Imaoka

    Version of Record online : 26 JUN 2011, DOI: 10.1111/j.2040-1124.2011.00137.x

  18. You have free access to this content
    The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 8, August 2014, Pages: 673–688, J. Seufert and B. Gallwitz

    Version of Record online : 16 JAN 2014, DOI: 10.1111/dom.12251

  19. You have full text access to this OnlineOpen article
    Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 4, April 2014, Pages: 376–380, K. Tatarkiewicz, C. Polizzi, C. Villescaz, L. J. D'Souza, Y. Wang, S. Janssen and D. G. Parkes

    Version of Record online : 9 DEC 2013, DOI: 10.1111/dom.12237

  20. You have full text access to this OnlineOpen article
    DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide

    Diabetic Medicine

    Volume 28, Issue 6, June 2011, Pages: 705–714, C. Wysham, R. Bergenstal, J. Malloy, P. Yan, B. Walsh, J. Malone and K. Taylor

    Version of Record online : 16 MAY 2011, DOI: 10.1111/j.1464-5491.2011.03301.x